Lipid-Based Nanomaterials for Drug Delivery Systems in Breast Cancer Therapy

Lekshmi Rethi¹, Chinmaya Mutalik¹, Dito Anurogo^{2

3}, Long-Sheng Lu^{1

4

5}, Hsiu-Yi Chu⁶, Sibidou Yougbaré⁷, Tsung-Rong Kuo^{1

8}, Tsai-Mu Cheng^{9

10}, Fu-Lun Chen^{11

12}

Affiliations

¹ International Ph.D. Program in Biomedical Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei 11031, Taiwan.
² International Ph.D. Program for Cell Therapy and Regeneration Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan.
³ Faculty of Medicine and Health Sciences, Universitas Muhammadiyah Makassar, Makassar City 90221, South Sulawesi, Indonesia.
⁴ Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei 11031, Taiwan.
⁵ Department of Radiation Oncology, Taipei Medical University Hospital, Taipei Medical University, Taipei 11031, Taiwan.
⁶ Ph.D. Program for Translational Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan.
⁷ Institut de Recherche en Sciences de la Santé/Direction Régionale du Centre Ouest (IRSS/DRCO), Nanoro BP 218, 11, Burkina Faso.
⁸ Graduate Institute of Nanomedicine and Medical Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei 11031, Taiwan.
⁹ Graduate Institute of Translational Medicine, College of Medicine and Technology, Taipei Medical University, Taipei 11031, Taiwan.
¹⁰ Taipei Heart Institute, Taipei Medical University, Taipei 11031, Taiwan.
¹¹ Department of Internal Medicine, Division of Infectious Diseases, Taipei Municipal Wan Fang Hospital, Taipei Medical University, Taipei 11031, Taiwan.
¹² Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan.

PMID: 36079985
PMCID: PMC9458017
DOI: 10.3390/nano12172948

Review

Lipid-Based Nanomaterials for Drug Delivery Systems in Breast Cancer Therapy

Lekshmi Rethi et al. Nanomaterials (Basel). 2022.

. 2022 Aug 26;12(17):2948.

doi: 10.3390/nano12172948.

Authors

Lekshmi Rethi¹, Chinmaya Mutalik¹, Dito Anurogo^{2

3}, Long-Sheng Lu^{1

4

5}, Hsiu-Yi Chu⁶, Sibidou Yougbaré⁷, Tsung-Rong Kuo^{1

8}, Tsai-Mu Cheng^{9

10}, Fu-Lun Chen^{11

12}

Affiliations

¹ International Ph.D. Program in Biomedical Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei 11031, Taiwan.
² International Ph.D. Program for Cell Therapy and Regeneration Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan.
³ Faculty of Medicine and Health Sciences, Universitas Muhammadiyah Makassar, Makassar City 90221, South Sulawesi, Indonesia.
⁴ Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei 11031, Taiwan.
⁵ Department of Radiation Oncology, Taipei Medical University Hospital, Taipei Medical University, Taipei 11031, Taiwan.
⁶ Ph.D. Program for Translational Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan.
⁷ Institut de Recherche en Sciences de la Santé/Direction Régionale du Centre Ouest (IRSS/DRCO), Nanoro BP 218, 11, Burkina Faso.
⁸ Graduate Institute of Nanomedicine and Medical Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei 11031, Taiwan.
⁹ Graduate Institute of Translational Medicine, College of Medicine and Technology, Taipei Medical University, Taipei 11031, Taiwan.
¹⁰ Taipei Heart Institute, Taipei Medical University, Taipei 11031, Taiwan.
¹¹ Department of Internal Medicine, Division of Infectious Diseases, Taipei Municipal Wan Fang Hospital, Taipei Medical University, Taipei 11031, Taiwan.
¹² Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan.

PMID: 36079985
PMCID: PMC9458017
DOI: 10.3390/nano12172948

Abstract

Globally, breast cancer is one of the most prevalent diseases, inducing critical intimidation to human health. Lipid-based nanomaterials have been successfully demonstrated as drug carriers for breast cancer treatment. To date, the development of a better drug delivery system based on lipid nanomaterials is still urgent to make the treatment and diagnosis easily accessible to breast cancer patients. In a drug delivery system, lipid nanomaterials have revealed distinctive features, including high biocompatibility and efficient drug delivery. Specifically, a targeted drug delivery system based on lipid nanomaterials has inherited the advantage of optimum dosage and low side effects. In this review, insights on currently used potential lipid-based nanomaterials are collected and introduced. The review sheds light on conjugation, targeting, diagnosis, treatment, and clinical significance of lipid-based nanomaterials to treat breast cancer. Furthermore, a brighter side of lipid-based nanomaterials as future potential drug delivery systems for breast cancer therapy is discussed.

Keywords: breast cancer; conjugation; drug delivery system; efficacy; exosomes; liposomes; micelles; safety; targeting.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

**Figure 1**
Schematic representation of specific targeted drug delivery strategy of Dox prodrug-loaded TNPHER2pep for HER2 overexpressing breast cancer cells. (A) Dissociation and association of expression of HER2 on epithelial cells within breast cancer lesions are many folds higher than that on healthy epithelial cells. On HER2 overexpressing breast cancer cells, TNPHER2pep liposome undergoes endocytosis (B) density of peptide and length of EG linker are designed, synthesized, and applied using both in vitro and in vivo methods to increase liposome cellular uptake in breast cancer cells. Reproduced with permission from ref. [86] Copyright © 2020, Elsevier.

**Figure 2**
Schematic representation of the liposomal drug delivery carrier system and treatment. The overexpressed estrogen receptors on cancer cells were targeted by estrone in vitro and in vivo. Reproduced with permission from ref. [88] Copyright © 2020, Elsevier.

**Figure 3**
Schematic representation of the tri-Bio-Lip effective drug delivery system to inhibit two kinds of cancer cell lines, mice breast cancer cell line (4T1) and human breast cancer cell lines (MCF-7), respectively. Reproduced with permission from ref. [89] Copyright © 2020, Elsevier.

**Figure 4**
Schematic representation of DTX-Lipoplex pH-responsive nano-drug delivery system in vitro and in vivo. Reproduced with permission from ref. [90] Copyright © 2020, Elsevier.

**Figure 5**
Schematic illustration of isolation of MSC-derived drug-loaded exosomes and efficacy evaluation of targeting agent, in vitro as well as in vivo, to eradicate metastatic breast cancer. Reproduced with permission from ref. [110] Copyright © 2019, MDPI.

**Figure 6**
Schematic illustration of a polymeric micelle-based drug delivery system, HA known to target CD44 receptors through COX-2 overexpressed factor on cancer cells and DOX loaded to inhibit breast cancer cells. Reproduced with permission from ref. [118] Copyright © 2020, Elsevier.

**Figure 7**
Schematic representation of a polymeric micelle-based drug delivery system, HA known to target CD44 receptors on TNBC cells and drug DOX loaded to inhibit metastasis of breast cancer by downregulating MMP-9 factor. Reproduced with permission from ref. [119] Copyright © 2020, Elsevier.

See this image and copyright information in PMC

References

1. Chang T.-W., Ko H., Huang W.-S., Chiu Y.-C., Yang L.-X., Chia Z.-C., Chin Y.-C., Chen Y.-J., Tsai Y.-T., Hsu C.-W., et al. Tannic acid-induced interfacial ligand-to-metal charge transfer and the phase transformation of Fe3O4 nanoparticles for the photothermal bacteria destruction. Chem. Eng. J. 2022;428:131237. doi: 10.1016/j.cej.2021.131237. - DOI
1. Hsu I.L., Yeh F.H., Chin Y.-C., Cheung C.I., Chia Z.C., Yang L.-X., Chen Y.-J., Cheng T.-Y., Wu S.-P., Tsai P.-J., et al. Multiplex antibacterial processes and risk in resistant phenotype by high oxidation-state nanoparticles: New killing process and mechanism investigations. Chem. Eng. J. 2021;409:128266. doi: 10.1016/j.cej.2020.128266. - DOI
1. Yang Y.-T., Hsu I.L., Cheng T.-Y., Wu W.-J., Lee C.-W., Li T.-J., Cheung C.I., Chin Y.-C., Chen H.-C., Chiu Y.-C., et al. Off-resonance SERS nanoprobe-targeted screen of biomarkers for antigens recognition of bladder normal and aggressive cancer cells. Anal. Chem. 2019;91:8213–8220. doi: 10.1021/acs.analchem.9b00775. - DOI - PubMed
1. Mutalik C., Okoro G., Krisnawati D.I., Jazidie A., Rahmawati E.Q., Rahayu D., Hsu W.-T., Kuo T.-R. Copper sulfide with morphology-dependent photodynamic and photothermal antibacterial activities. J. Colloid Interface Sci. 2022;607:1825–1835. doi: 10.1016/j.jcis.2021.10.019. - DOI - PubMed
1. Mutalik C., Krisnawati D.I., Patil S.B., Khafid M., Atmojo D.S., Santoso P., Lu S.-C., Wang D.-Y., Kuo T.-R. Phase-dependent MoS2 nanoflowers for light-driven antibacterial application. ACS Sustain. Chem. Eng. 2021;9:7904–7912. doi: 10.1021/acssuschemeng.1c01868. - DOI

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Lipid-Based Nanomaterials for Drug Delivery Systems in Breast Cancer Therapy

Affiliations

Lipid-Based Nanomaterials for Drug Delivery Systems in Breast Cancer Therapy

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

References

Publication types

Grants and funding

LinkOut - more resources

Full Text Sources